2. Academic Validation
  3. Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis

Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis

  • Cell Rep Med. 2025 Apr 15;6(4):102047. doi: 10.1016/j.xcrm.2025.102047.
Dong-Hyun Kim 1,  Gona Choi 1,  Eun-Bi Song 1,  Hanna Lee 2,  Jaehui Kim 3,  Young-Saeng Jang 3,  JinJoo Park 4,  Susan Chi 4,  Jaekyu Han 4,  Sun-Mi Kim 4,  Dongyoon Kim 5,  Soo Han Bae 6,  Hye Won Lee 7,  Jun Yong Park 7,  Seung Goo Kang 8,  Sang-Hoon Cha 9,  Yong-Hyun Han 10
Affiliations

Affiliations

  • 1 Laboratory of Pathology and Physiology, College of Pharmacy, Kangwon National University, Chuncheon 24341, South Korea.
  • 2 Laboratory of Pathology and Physiology, College of Pharmacy, Kangwon National University, Chuncheon 24341, South Korea; Multidimensional Genomics Research Center, Kangwon National University, Chuncheon 24341, South Korea.
  • 3 Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, South Korea; Institute of Bioscience and Biotechnology, College of Biomedical Science, Kangwon National University, Chuncheon 24341, South Korea.
  • 4 AprilBio Co., Ltd, Biomedical Science Building, Kangwon National University, Chuncheon 24341, South Korea.
  • 5 Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • 6 Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, South Korea.
  • 7 Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, South Korea.
  • 8 Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, South Korea; Institute of Bioscience and Biotechnology, College of Biomedical Science, Kangwon National University, Chuncheon 24341, South Korea. Electronic address: sgkang@kangwon.ac.kr.
  • 9 Institute of Bioscience and Biotechnology, College of Biomedical Science, Kangwon National University, Chuncheon 24341, South Korea; AprilBio Co., Ltd, Biomedical Science Building, Kangwon National University, Chuncheon 24341, South Korea. Electronic address: chash@aprilbio.com.
  • 10 Laboratory of Pathology and Physiology, College of Pharmacy, Kangwon National University, Chuncheon 24341, South Korea; Multidimensional Genomics Research Center, Kangwon National University, Chuncheon 24341, South Korea. Electronic address: yhhan1015@kangwon.ac.kr.
PMID: 40239621 DOI: 10.1016/j.xcrm.2025.102047
Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease characterized by inflammation and fibrosis, with enhanced interleukin-18 (IL-18) signaling. IL-18-binding protein (IL-18BP) neutralizes IL-18, but its therapeutic potential in MASH is unclear. We find elevated IL-18BP and IL-18 levels in patients with MASH and mice, with free IL-18 correlating with disease severity. IL-18 stimulates interferon-gamma (IFNγ) production in CD4 T cells, increasing hepatic IL-18BP. IL-18BP-deficient mice show worsened liver inflammation and fibrosis. We develop a human IL-18BP biologics (APB-R3) and inject it to mice to evaluate its pharmacologic efficacy. APB-R3 significantly improves MASH in reducing fibrosis and inflammation and inhibits hepatic stellate cell activation via the cGMP pathway. This study proposes that abrogation of IL-18 signaling by boosting IL-18BP can strongly inhibit the development of MASH-induced fibrosis, and our engineered IL-18BP biologics can become a promising therapeutic candidate for curing MASH.

Keywords

APB-R3; IFNγ; IL-18BP; MASH; fibrosis; hepatic stellate cell.

Figures
Products